Generate Biomedicines, Inc. (GENB) Stock Price & Analysis
Generate Biomedicines, Inc. (GENB) closed at USD 13.06 on Thursday, October 15, 2026, up 4.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 12.52; the Oct 15, 2026 session ranged USD 12.43–13.16 on volume of 974,834 shares. Market capitalization is $1.68B, with a 52-week range of USD 11–22.67 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GENB.md
Key facts (GENB)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 27 (range 22–30).
- Total return with dividends: 1Y +3.2% vs S&P 500 +18.1%; 5Y +3.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.55, revenue estimate $7.8M.
Analysts (GENB)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 27 (low 22, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| 2026-08-28 | HC Wainwright & Co. | Target raised | Buy | $25 → $30 |
Total return (dividends reinvested) (GENB)
| 1Y (from 2026-02-27) | 5Y (from 2026-02-23) | |
|---|---|---|
| Total return | +3.2% | +3.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 86.9% | 71.2% |
| Max drawdown | -39.8% (Aug 2026→Oct 2026) | -25.0% (Jun 2026→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 13.06 |
|---|---|
| Change | ▲ 4.31% (up) |
| Previous Close | USD 12.52 |
| Open | USD 12.52 |
| Day Range | USD 12.43 – 13.16 |
| 52-Week Range | USD 11 – 22.67 |
| Volume | 974,834 shares |
| Market Cap | $1.68B |
| Exchange | NMS |
Technical Analysis (GENB)
Nexqual's technical model rates GENB "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.02 (neutral) |
| vs SMA50 | Below (USD 15.41) |
| MACD | -0.77 (negative) |
Analyst Ratings (GENB)
Wall Street analysts rate GENB "Buy" based on 6 analysts, with a mean price target of USD 27 (range USD 22–30), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 27 |
| High Target | USD 30 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (GENB)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.55 |
| Revenue Estimate | $7.75M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.52 vs est -0.49 ▼ miss |
| 2026-03-31 | USD -1.07 vs est -0.51 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (GENB)
| Total Revenue | $26.48M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -37.70% |
| Gross Margin | +0.00% |
| Operating Margin | -1134.21% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.14 |
| Current Ratio | 8.3 |
| Total Cash | $457.42M |
| Total Debt | $62.63M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (GENB)
Nexqual rates Generate Biomedicines, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -38% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $457M cash vs $63M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$237M (TTM) |
| Efficiency | Mixed — No data |
Ownership (GENB)
| Insider Ownership | +14.05% |
|---|---|
| Institutional Ownership | +77.62% |
| Shares Outstanding | 128.35M |
| Float | 60.45M |
| Short % of Float | +9.92% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (GENB)
Generate Biomedicines, Inc. is led by Michael T. Nally (age 49), CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| CEO & Director | Michael T. Nally (age 49) |
|---|---|
| President & CFO | Jason E. Silvers (age 53) |
| Co-Founder & CTO | Gevorg Grigoryan (age 44) |
| Chief Scientific Officer | Aarif Khakoo (age 54) |
| Senior Vice President of Discovery Strategy | Daria Hazuda |
Major Backers & Investors (GENB)
Notable institutional backers of Generate Biomedicines, Inc. include Flagship Pioneering LLC, FMR, LLC, Capital Group, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flagship Pioneering LLC | 48.83% |
| FMR, LLC | 4.07% |
| Capital Group | 3.28% |
| SmallCap World Fund Inc | 2.92% |
| Fidelity | 2.67% |
| Braidwell LP | 2.56% |
| Price (T.Rowe) Associates Inc | 1.68% |
| NORGES BANK | 1.63% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.76% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt